Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering

Benzinga · Jan 22 17:31

On January 22, 2024, Virax Biolabs Group Limited, a Cayman Islands exempted company (the "Company"), entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC (the "Sales Agent"), acting as the Company's sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, its ordinary shares, par value $0.001 per share (the "Ordinary Shares"), having an aggregate offering amount of up to $1,455,029. On January 22, 2024, pursuant to the Sales Agreement, the Company filed a prospectus supplement, including an accompanying base prospectus, dated December 15, 2023, forming a part of its effective registration statement on Form F-3 (File No. 333-275893), initially filed with the Securities and Exchange Commission on December 5, 2023.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering

Risk Disclaimer